STAT+: Biogen to acquire immunology biotech Apellis for $5.6 billion
Why it matters: Biogen expands its portfolio with two commercial immunology assets, including Syfovre, which generated $587 million in sales.
- Biogen will acquire Apellis Pharmaceuticals for an upfront payment of approximately $5.6 billion.
- Apellis shareholders are set to receive $41 per share, with an additional $4 per share possible if Syfovre sales targets are met.
- Syfovre, an Apellis drug approved in 2023, treats geographic atrophy secondary to age-related macular degeneration and generated $587 million in sales last year.
Biogen announced its acquisition of immunology biotech Apellis for an upfront payment of $5.6 billion, significantly expanding its portfolio with two approved immunology drugs. This deal, valued at $41 per share with potential additional payments, more than doubles Apellis's Monday closing price and brings Biogen Syfovre, a drug for advanced macular degeneration that generated $587 million in sales last year.
